Effect of Probiotics in Prevention of Neonatal Jaundice

Document Type : Original Article


1 Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran

2 Neonatal Research Center, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran

3 Neonatal Research Center, Department of Pediatrics, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran

4 Clinical Research Development Center, Mashhad University of Medical Sciences, Mashhad, Iran


Background: Jaundice is the most common problem among neonates. Although neonatal jaundice is highly prevalent in Iran and the prevention and treatment of this disease is incredibly important, few studies have been conducted on the effect of probiotics in the prevention of hyperbilirubinemia in Iran so far. Considering the contradictory results in this regard, this study was conducted to investigate the effect of probiotics in preventing jaundice among neonates.
Methods: The statistical population of this three-blinded clinical trial on the first of January 2021 consisted of 196 neonates who were divided into two groups of placebo and intervention. The neonates with a gestational age of more than 37 weeks, birth weight of more than 2,500 grams, and without risk factors for jaundice were included in the study after that the research objectives and procedures were explained to their parents and their informed consent was obtained. Patients were randomly divided into the intervention and placebo groups. The intervention group underwent treatment with probiotics (1010 Saccharomyces boulardii daily for 5 days), while the other group received treatment with a placebo. The level of bilirubin was measured with a skin bilirubin meter and, if necessary (i.e., bilirubin more than 15), a blood test was administered before the intervention and on the third and fifth days after the intervention. The effect of probiotics on jaundice was compared in the two groups.
Results: Based on the study results, the level of forehead and chest bilirubin was not significantly different between the study groups before the intervention and 3 and 5 days after the intervention (P> 0.05). In cases that skin bilirubin levels were higher than 15 on the fifth day ,the mean serum bilirubin level was obtained at 15.71±0.99 mg/dl and 17.42±1.17 mg/dl in the intervention and placebo group, respectively, which was statistically significant (P = 0.03).
Conclusion The results of this study showed that the use of Saccharomyces boulardi decreased the level of serum bilirubin (P=0.03).


  1. Maisels MJ, Kring E. Length of stay, jaundice, and hospital readmission. Pediatrics. 1998;101(6):995-8.
  2. Lauer BJ, Spector ND. Hyperbilirubinemia in the newborn. Pediatrics in Review-Elk Grove. 2011;32(8):341-49.
  3. Thomas M, Hardikar W, Greaves RF, Tingay DG, Loh TP, Ignjatovic V, Newall F, Rajapaksa AE, et al. Mechanism of bilirubin elimination in urine: insights and prospects for neonatal jaundice. Clin Chem Lab Med. 2021;59(6):1025-33.
  4. Goyal M, Srivastava A. The study of association of fetal and maternal factors in the occurrence of hyperbilirubinemia in early neonatal period. Int J Res Med Sci. 2020;8(3):967-73.
  5. American Academy of Pediatrics Subcommittee on Hyperbilirubinemia. Management of hyperbili-rubinemia in the newborn infant 35 or more weeks of gestation. Pediatrics. 2004;114(1):297-316.
  6. Mercier CE, Barry SE, Paul K, Delaney TV, Horbar JD, Wasserman RC, Berry P, Shaw JS, et al. Improving newborn preventive services at the birth hospitalization: a collaborative, hospital-based quality-improvement project. Pediatrics. 2007;
  7. Jafarian AH. Matrix metalloproteinase-9 (MMP-9) Expression in Non-Small Cell Lung Carcinoma and Its Association with Clinicopathologic Factors. Iran J Pathol. 2020;15(4):326-33.
  8. Homayouni A, Bagheri N, Mohammad-Alizadeh-Charandabi S, Kashani N, Mobaraki-Asl N, Mirghafurvand M, Asgharian H, Ansari F, Pourjafar H, et al. Prevention of gestational diabetes mellitus (GDM) and probiotics: mechanism of action: a review. Curr Diabetes Rev. 2020;16(6):538-45.
  9. Chen K, Yuan T. The role of microbiota in neonatal hyperbilirubinemia. Am J Transl Res. 2020;
  10. Torkaman M, Mottaghizadeh F, Khosravi MH, Najafian B, Amirsalari S, Afsharpaiman S, et al. The effect of probiotics on reducing hospitalization duration in infants with hyperbilirubinemia. Iran J Pediatr. 2017, 27(1):1-6.
  11. Marcdante K, Kliegman RM. Nelson Essentials of Pediatrics-E-Book: First South Asia Edition. Elsevier sci. 2016.
  12. Demirel G, Celik IH, Erdeve O, Dilmen U. Impact of probiotics on the course of indirect hyperbilirubinemia and phototherapy duration in very low birth weight infants. J Matern Fetal Neonatal Med. 2013;26(2):215-8.
  13. Armanian AM, Barekatain B, Hoseinzadeh M, Salehimehr N. J Matern Fetal Neonatal Med. 2016;29(18):3009-13.
  14. Suganthi V, Das AG. Role of Saccharomyces boulardii in reduction of neonatal hyperbilirubinemia. J Clin Diagn Res. 2016;10(11):SC12-SC15.
  15. Liu W, Liu H, Wang T, Tang X. Therapeutic effects of probiotics on neonatal jaundice. Pak J Med Sci. 2015;31(5):1172-5.
  16. Deshmukh J, Deshmukh M, Patole S. Probiotics for the management of neonatal hyperbilirubinemia: a systematic review of randomized controlled trials. J Matern Fetal Neonatal Med. 2019;32(1):154-63.
  17. Fan S, Zhang K, Zheng F, Zhang J, Wu Z, Lv A, Ma Y, Fang X, Zhang J, et al. Analysis of the Effect of Phototherapy on Intestinal Probiotics and Its Metabolism in Newborns With Jaundice. Res Sq. 2021:1-16.